^
    Back
    Association details:
    Biomarker:SRRM4 overexpression
    Cancer:Bladder Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Int J Urol
    Title:

    Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer

    Published date:
    08/21/2023
    Excerpt:
    Patients who responded to atezolizumab had higher SRRM4 and lower NPHS1 and TMEM72 expression than the non-responders.
    DOI:
    https://doi.org/10.1111/iju.15276